STOCK TITAN

Castle Biosciences - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.

Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.

Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data

Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) presented new data on its skin cancer test portfolio at the 2023 Winter Clinical Dermatology Conference in Hawaii. Findings on DecisionDx®-Melanoma indicate it can accurately identify patients with high-risk tumor biology among those with negative lymph nodes. In a cohort of 3,271 patients, low-risk results showed a 99.7% three-year melanoma-specific survival rate versus 91.8% for high-risk individuals. Additionally, a new clinical algorithm for DecisionDx®-SCC offers a framework for managing high-risk cutaneous squamous cell carcinoma according to NCCN guidelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary

Castle Biosciences (NASDAQ: CSTL) announced preliminary results for 2022, expecting total revenue to reach $132$137 million. The company delivered 44,338 test reports, marking a 58% increase from 2021, with significant growth in DecisionDx®-Melanoma tests.

Year-end cash and equivalents are projected at approximately $259 million. Despite these positive metrics, the company cautioned about uncertainties affecting future results, including macroeconomic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary

Castle Biosciences (CSTL) announced findings from a study in collaboration with the Melanoma Research Foundation, revealing that 90% of uveal melanoma (UM) patients value prognostic testing at diagnosis. The DecisionDx-UM test reportedly provides insights into personalized treatment options, significantly reduces decision regret, and is now the standard of care in many US oncology practices. Despite various risk classifications, most patients indicated comparable decision regret levels. The study underscores the importance of personalized information for patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.17%
Tags
none
Rhea-AI Summary

Castle Biosciences, Inc. (NASDAQ: CSTL) announced new data at the ASDP 59th Annual Meeting indicating that the DecisionDx-SCC test can provide significant risk stratification for patients with cutaneous squamous cell carcinoma (cSCC) and uncertain tumor differentiation. This study, which involved 420 patients, revealed that 40% had changing BWH staging based on differentiation status alterations. Furthermore, low-risk patients demonstrated a three-year metastasis-free survival rate of 90.1%, outperforming moderate and high-risk groups, underscoring the test's value in guiding treatment decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) reported a 58% revenue increase to $37.0 million in Q3 2022, delivering a record 12,114 test reports, a 57% rise from Q3 2021. Adjusted revenues reached $37.3 million, marking a similar 58% growth. The company raised its 2022 revenue guidance to $132-137 million from $130-135 million. Despite the strong top-line growth, Castle Biosciences experienced a net loss of $(20.2) million for the quarter, worsening from $(11.8) million in Q3 2021. Gross margins were reported at 70%, with expectations for positive net operating cash flow by 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
Rhea-AI Summary

Castle Biosciences, Inc. (NASDAQ: CSTL) will present company overviews at multiple investor conferences this November. These include the Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. ET, the Stephens Annual Investment Conference on Nov. 16, 2022, at 11:00 a.m. ET, and the Canaccord Genuity MedTech Conference on Nov. 17, 2022, at 11:30 a.m. ET. Live webcasts will be accessible on their website, with replays available post-event.

Castle focuses on diagnostics, offering tests for skin cancers and other diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary

Castle Biosciences (CSTL) announced the publication of clinical utility data in Cancer Investigation, revealing that clinicians are effectively using the DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma (SCC) patients. In the study, 98.1% of 2,503 samples were tested, with 68.8% classified as low-risk. The study reinforces the importance of risk assessment beyond traditional methods, as 75% of samples had multiple high-risk factors. Results indicate that the test aids in aligning treatment plans with patients' metastatic risks, potentially reducing overtreatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
none
-
Rhea-AI Summary

Castle Biosciences (CSTL) announced new data demonstrating the effectiveness of DecisionDx-Melanoma and DecisionDx-UM in accurately predicting the risk of death associated with melanoma in real-world patients. In collaboration with the National Cancer Institute, the studies showed that these tests can help identify low-risk patients who may avoid unnecessary therapies. The findings highlight potential healthcare cost reductions and improved treatment decisions, as evidenced by significant survival rate differences based on test results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
Rhea-AI Summary

Castle Biosciences, Inc. (NASDAQ: CSTL) announced at the 2022 ACG Annual Scientific Meeting that its TissueCypher® Barrett's Esophagus Test significantly enhances management decisions for patients with low-grade dysplasia (LGD). The study showed that utilizing TissueCypher results led to a 58.4% likelihood of patients receiving appropriate management compared to 9.1% with standard care. This test aims to standardize care, reduce unnecessary therapies, and potentially lower esophageal cancer risks. The findings suggest a substantial impact on patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.57%
Tags
none
Castle Biosciences

Nasdaq:CSTL

CSTL Rankings

CSTL Stock Data

620.45M
28.04M
3.35%
93.97%
6.48%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD